The optimal duration of dual antiplatelet therapy (DAPT) in patients with ischaemic cardiovascular (CV) disease is still debated. Previous meta-analyses reported conflicting results about prolonged DAPT on mortality and major CV events. Aim of this study was to assess the effects of prolonged vs. no/short-term DAPT on myocardial infarction (MI), stroke, bleeding, and mortality
Dual antiplatelet therapy (DAPT) prevents recurrent ischemic events after an acute coronary syndrome...
BACKGROUND: Dual antiplatelet therapy (DAPT) remains the cornerstone therapy in the prevention of is...
This study sought to investigate the clinical outcome of patients treated with percutaneous coronary...
The optimal duration of dual antiplatelet therapy (DAPT) in patients with ischaemic cardiovascular (...
AIMS: The optimal duration of dual antiplatelet therapy (DAPT) in patients with ischaemic cardiovasc...
Background Dual antiplatelet therapy (DAPT) has important implications for clinical outcomes in coro...
BackgroundTreatment with aspirin and a P2Y12 inhibitor is commonly used in patients with cardiovascu...
AIMS Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT) in a va...
Whether prolonged dual antiplatelet therapy (DAPT) is more protective in patients with CKD and drug-...
textabstractOBJECTIVE: To assess the benefits and risks of short term (12 months) dual antiplatelet ...
The purpose of the study was to evaluate the optimal duration of dual antiplatelet therapy (DAPT) af...
Aims Optimal duration of dual antiplatelet therapy (DAPT) in patients with concomitant indication to...
The purpose of the study was to evaluate the optimal duration of dual antiplatelet therapy (DAPT) af...
Patients experiencing an acute coronary syndrome are exposed to an increased residual risk of recurr...
Background: Optimal duration of dual antiplatelet therapy (DAPT) in patients undergoing complex perc...
Dual antiplatelet therapy (DAPT) prevents recurrent ischemic events after an acute coronary syndrome...
BACKGROUND: Dual antiplatelet therapy (DAPT) remains the cornerstone therapy in the prevention of is...
This study sought to investigate the clinical outcome of patients treated with percutaneous coronary...
The optimal duration of dual antiplatelet therapy (DAPT) in patients with ischaemic cardiovascular (...
AIMS: The optimal duration of dual antiplatelet therapy (DAPT) in patients with ischaemic cardiovasc...
Background Dual antiplatelet therapy (DAPT) has important implications for clinical outcomes in coro...
BackgroundTreatment with aspirin and a P2Y12 inhibitor is commonly used in patients with cardiovascu...
AIMS Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT) in a va...
Whether prolonged dual antiplatelet therapy (DAPT) is more protective in patients with CKD and drug-...
textabstractOBJECTIVE: To assess the benefits and risks of short term (12 months) dual antiplatelet ...
The purpose of the study was to evaluate the optimal duration of dual antiplatelet therapy (DAPT) af...
Aims Optimal duration of dual antiplatelet therapy (DAPT) in patients with concomitant indication to...
The purpose of the study was to evaluate the optimal duration of dual antiplatelet therapy (DAPT) af...
Patients experiencing an acute coronary syndrome are exposed to an increased residual risk of recurr...
Background: Optimal duration of dual antiplatelet therapy (DAPT) in patients undergoing complex perc...
Dual antiplatelet therapy (DAPT) prevents recurrent ischemic events after an acute coronary syndrome...
BACKGROUND: Dual antiplatelet therapy (DAPT) remains the cornerstone therapy in the prevention of is...
This study sought to investigate the clinical outcome of patients treated with percutaneous coronary...